Concurrent chemoradiotherapy with low dose weekly gemcitabine in medically inoperable muscle-invasive bladder cancer patients

Atasoy B. M., Dane F., Cetin I. A., Ozgen Z., Kefeli A. U., Ibrahimov R., ...Daha Fazla

Clinical and Translational Oncology, cilt.16, sa.1, ss.91-95, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16 Sayı: 1
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1007/s12094-013-1047-8
  • Dergi Adı: Clinical and Translational Oncology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.91-95
  • Anahtar Kelimeler: Bladder cancer, Concurrent gemcitabine, Medically unfit patients, Radiotherapy, COMBINED-MODALITY PROGRAM, RADIATION-THERAPY, PHASE-I, NEOADJUVANT CHEMOTHERAPY, ORGAN PRESERVATION, RADIOTHERAPY, TRIAL, CISPLATIN
  • Marmara Üniversitesi Adresli: Evet

Özet

Purpose: We aimed to determine the efficacy and the toxicity of low dose weekly gemcitabine with radiation therapy in medically unfit muscle-invasive bladder cancer patients. Methods: Twenty-six patients were included into the retrospective analysis. Weekly gemcitabine was administered 75 mg/m2 with a median dose of 63 Gy radiation therapy. Clinical target volume was defined as the urinary bladder only in conformal treatment planning. Results: Median follow-up was 51 months (range 14-118 months). Complete response rate was 62.5 %. The 5-year local progression-free survival, disease-specific survival and overall survival rates were 40.6, 59.5 and 58.5 %, respectively. Concurrent chemotherapy was continued in 80.7 % of patients without any interruption. Gemcitabine was stopped due to grade 3 thrombocytopenia (n = 1), cardiac angina (n = 1), chronic obstructive pulmonary disease exacerbation (n = 1) or patients' reluctance (n = 2). Conclusions: Low dose weekly gemcitabine with concurrent radiotherapy is a tolerable regimen and have comparable outcomes with platinum-based combined treatments in muscle-invasive bladder cancer. Prospective randomized trials can help in understanding the safety and efficacy of this treatment specially in medically unfit patients. © 2013 Federación de Sociedades Españolas de Oncología (FESEO).